How the FDA Regulates PRP and Who May Inject It
How does the FDA regulate PRP preparation, and who is allowed to handle the blood product?
Two different levels of government are answering two different questions about your treatment, and mixing them up is where nearly all the confusion starts. The federal side cares about the machine that spins your blood and the biological status of what comes out of it. Whether the person holding the needle is allowed to hold it is a state question, and that's the one that actually decides who touches you.
| What's In Question | Federal (FDA) | State Law |
|---|---|---|
| Kits and centrifuges | Class II devices, 510(k) cleared | Not addressed |
| The concentrate itself | Autologous blood component when drawn, spun, and returned in one session | Not addressed |
| Who draws, spins, injects | Silent | Medical and nursing practice acts, delegation rules |
| Certification to draw blood | None required | Varies by state; California requires certification |
Concentrate drawn from you, spun without additives that change its biology, and returned to you in a single procedure is regulated as an autologous blood component rather than a drug, so no federal approval applies and state practice acts alone decide who may draw, process, and inject it.
What legal framework does the FDA use to classify autologous blood products such as platelet rich plasma?
The framework has nothing to do with hair or joints. It turns entirely on what the material is and where it travels, which is why a rule written for tissue banking ends up governing your scalp appointment. Whole blood and blood components are carved out of the human cells and tissue rules, and your own concentrated platelets, minimally handled and given straight back to you, sit inside that carve-out.
- Section 361 status: No premarket approval, treated as a communicable disease control matter.
- Section 351 status: A biological drug needing an investigational application or a license.
- What flips the switch: Culturing, expanding, adding substances, storing for later, or giving it to someone else.
A Section 361 autologous blood product requires no premarket submission, while a preparation that's cultured, expanded, combined with outside substances, banked, or transferred to a second person falls under Section 351 and needs an investigational new drug application or a biologics license before it can be used.
What do minimal manipulation and homologous use mean in practice, and when does a preparation lose its exempt status?
Most people assume minimal manipulation is about how much effort goes into the sample. It isn't. It asks one question: did the processing change what the material biologically is? Spinning platelets apart by density concentrates something that was already in your blood, so a straight centrifuge cycle sits comfortably inside the line, and the conditions people actually break are the boring logistical ones.
A preparation keeps its exempt status only while it stays autologous, minimally manipulated, and same-procedure, so a tube that leaves the treatment area, is stored overnight, or is held for a rescheduled patient has changed regulatory category rather than simply become inconvenient.
What does FDA clearance of a PRP kit or centrifuge actually cover, and what does it not cover?
Cleared and approved aren't synonyms, and the gap between those two words explains most of the misleading advertising you'll run into. Clearance means the manufacturer showed its device is substantially equivalent to one already on the market, which is a comparison exercise about hardware, not a trial about whether injecting the result regrows your hair. When a clinic advertises an FDA approved hair treatment, the honest translation is that there's a cleared centrifuge on the counter being used outside its cleared labeling.
| Criteria | Closed Single-Use Cleared Kit | Improvised Tube Protocol |
|---|---|---|
| Cleared for this use | Yes, though the indication is usually orthopedic | No |
| Air exposure | None between draw and injection | At every open transfer |
| Platelet yield | Reasonably reproducible, fixed geometry | Swings widely with operator technique |
| Cost | Higher per patient | Cheaper |
FDA clearance of a kit or centrifuge is a substantial equivalence finding about the device only, so a cleared indication written around preparing platelet rich plasma for orthopedic use is never an agency finding that scalp injection regrows hair.
Who is legally permitted to draw the patient's blood in a clinical setting?
Venipuncture is one of the most widely delegated acts in medicine, which is exactly why it tells you so little about a clinic's overall standards. Plenty of people can legally hold that needle. What varies wildly by state is who's allowed to supervise them and from how far away.
Blood draw authority is set entirely by state practice acts, so unlicensed personnel may draw only under a licensed practitioner's documented delegation and supervision, and a handful of states including California require formal phlebotomy certification on top of that.
Who may process the sample and prepare the final concentrate once the blood has been drawn?
This is the step you'll never think to ask about, and it's the step where the quality of what goes back into your scalp is actually decided. The law treats spinning a tube as a technical task a practitioner can hand to trained staff, which is permissive enough to hide an enormous practical spread. A practice that treats preparation as an afterthought can hand you something barely more concentrated than whole blood and still charge you for a concentrate.
- Spin variables: Speed, duration, and single versus double spin all move the final platelet count substantially.
- Handling variables: How the buffy coat is drawn off and how gently the concentrate is resuspended change the yield.
- Written protocol: Fixed device, fixed spin programme, stated target concentration factor, named trained operator, log entry per patient.
- Ownership: The delegating practitioner owns the outcome, so delegation goes to a specific competent person, not whoever's free.
Responsibility for the prepared concentrate never transfers with the task, so the supervising practitioner who delegated the preparation owns the result and the delegation must be to a specific individual trained and signed off on a written spin protocol.
What laboratory oversight rules apply to a clinic that spins and prepares blood on site?
The trigger here is purpose, not equipment. Federal laboratory rules attach to testing human specimens to inform diagnosis or treatment decisions, and spinning a tube to make an injectate isn't a test. Start measuring something and acting on the number, though, and the office has walked into the certification system.
Laboratory certification attaches to testing human specimens for diagnosis or treatment decisions rather than to preparation, so a clinic that only spins a tube usually needs no certificate, while running a platelet count or hematocrit in house requires one.
What bloodborne pathogen and infection control requirements govern the staff who handle the sample?
I don't want you sitting in a room where the corner-cutting is invisible to you, so here's what a compliant practice is actually obligated to do. Every practice that handles human blood is covered by workplace bloodborne pathogen rules, and those obligations are specific and auditable rather than aspirational. The risk that's particular to this procedure hides in the transfer steps, where a cap comes off and plasma moves between vessels.
- Written exposure control plan: Reviewed at least annually, listing every task carrying exposure risk.
- Engineering controls first: Safety-engineered needles and a rigid sharps container within arm's reach, not a rule about being careful.
- Needle handling: Bending, recapping, or removing contaminated needles is prohibited unless unavoidable, then only one-handed or with a device.
- Hepatitis B vaccination: Offered at the employer's expense to anyone with anticipated exposure, with any declination documented in writing.
Employers must provide a written exposure control plan reviewed annually, safety-engineered sharps, gloves for every draw and open-tube handling, hepatitis B vaccination at their own expense, and training at hire that repeats every year.
How must a sample be labeled and tracked so it is returned to the correct patient?
The worst realistic thing that can happen to you here isn't a disappointing result. It's receiving somebody else's blood, which turns a cosmetic appointment into a transfusion reaction and a possible bloodborne infection. The controls that stop it are borrowed straight from transfusion practice, they're simple, and they erode fast in a clinic running several people at once.
- Identify at the draw: You state your own identifying details rather than confirming what a staff member reads out to you.
- Label at the bedside: The tube is labeled in front of you before it leaves your side, never in advance and never in a batch.
- Keep it physically with you: The sample stays in the room, ideally in sight, and anything that left the room isn't injected.
- Re-verify at injection: Your identity is confirmed aloud in the room before the needle goes in.
- Record the session: Patient, date and time of draw, kit device and lot, spin protocol, who prepared it, who injected it.
A single-session preparation should never leave the patient's room, and the record must name the patient, the draw date and time, the kit device and lot number, the spin protocol, the person who prepared it, the person who injected it, and confirmation that identity was re-verified at injection.
Which marketing claims about platelet concentrate treatment attract regulatory enforcement, and what are the consequences?
Advertising gets policed separately from products, and by a different agency altogether, so a clinic can be perfectly clean on the medicine and still be exposed on its website. The standard is competent and reliable scientific evidence, which means the substantiation has to exist before the claim goes up, not after somebody asks for it. Treat a practice's marketing as evidence in its own right about how it handles facts it could easily have checked.
Health advertising is held to a competent and reliable scientific evidence standard that requires substantiation in hand before a claim is published, and consequences run from a warning letter and mandatory corrective advertising to civil penalties plus separate state board action against the individual license.
